Pfizer Inc. (PFE)
Company overview
A large global pharma company whose challenge is securing new growth drivers after COVID-19 vaccine and treatment revenue. It bolstered its oncology portfolio with the Seagen acquisition.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Pfizer Inc. is classified under the Biotech & Health sector. See peers below.
PFE revenue by segment summary
SEC 10-Q · segment totals cross-checked against total revenue
2026-03-29 revenue was $14.4B, +5.4% YoY.
The largest segment is Biopharma, 98.0% of revenue — a highly concentrated structure.
Recent revenue growth was led mainly by the Biopharma segment (about 98% of the increase).
Full segment weights, YoY changes, and an AI synthesis are available in the detailed analysis.
PFE segment revenue mix trend
Quarterly change in segment revenue share · verified from SEC filings
ETFs holding Pfizer Inc.
Per SEC N-PORT · 2026-03-31 · by weight · factual
PFE on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — valuation and growth vs the Biotech & Health average
Peers · Biotech & Health
PFE FAQ
What is Pfizer Inc. (PFE)?
A large global pharma company whose challenge is securing new growth drivers after COVID-19 vaccine and treatment revenue. It bolstered its oncology portfolio with the Seagen acquisition.
What sector is Pfizer Inc. in?
Pfizer Inc. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Pfizer Inc.'s main revenue segments?
The largest segment is Biopharma, about 98.0% of revenue. Segment totals are cross-checked against total revenue from SEC filings.
Where can I analyze Pfizer Inc. (PFE) stock?
On Stocklore you can see PFE's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, 45-day delay), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.